474799-41-2

Usage

Uses

Used in Chemical Research:
6-Nitrooxidole is used as a research compound for [application reason], contributing to the advancement of scientific knowledge in the field of organic chemistry.
Used in Pharmaceutical Industry:
6-Nitrooxidole is used as a potential pharmaceutical intermediate for [application reason], such as the synthesis of new drugs or the development of novel therapeutic agents.
Used in Material Science:
6-Nitrooxidole is used as a component in the development of new materials for [application reason], such as the creation of novel polymers or the improvement of existing materials with enhanced properties.
Note: The specific application reasons for 6-Nitrooxidole are not provided in the materials, so they are left as placeholders to be filled in with accurate information when available.

InChI:InChI=1/C8H6N2O3/c11-8-3-5-1-2-6(10(12)13)4-7(5)9-8/h1-2,4H,3H2,(H,9,11)

Upstream product

• 55233-05-1 t-Butyl 2-chloro-5-nitrobenzoate 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 4950-04-3 diethyl (2,4-dinitrophenyl)malonate 
• 185433-47-0 3,3-bis(methoxycarbonyl)-6-nitroindolin-2-one 
• 58605-12-2 (2,4-dinitro-phenyl)-acetic acid methyl ester 

Downstream Products

• 1093095-09-0 C₁₉H₁₆N₂O₅ 
• 1168152-01-9 (E)-1-acetyl-3-(ethoxy-phenyl-methylene)-6-nitroindolin-2-one 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a newtreatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacological cancer treatment. Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases. In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile. Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with additional efficacy on pericyctes and smooth muscle cells. In contrast, no direct inhibition of tumor cell proliferation was observed. Compounds 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated. The triple angiokinase inhibitor 3 is currently in phase III clinical trials for the treatment of nonsmall cell lung cancer.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

NEW COMPOUNDS

The present invention encompasses compounds of general Formula (I) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation

INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER

The present invention encompasses compounds of general formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

Non-peptidic NPY Y2 receptor inhibitors

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.